Dynamics in Post-pandemic Global Opioid-induced Constipation Industry: Supply and Demand, Markets and Prices 2021-2027

Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Opioid-induced Constipation Market Status and Forecast (2016-2027)
  • 1.3.2 Global Opioid-induced Constipation Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Opioid-induced Constipation Supply by Company

• 2.1 Global Opioid-induced Constipation Sales Value by Company
• 2.2 Opioid-induced Constipation Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Opioid-induced Constipation Market Status by Category

• 3.1 Opioid-induced Constipation Category Introduction
  • 3.1.1 Solid
  • 3.1.2 Liquid
• 3.2 Global Opioid-induced Constipation Market by Category
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Opioid-induced Constipation Market Status by End User/Segment

• 4.1 Opioid-induced Constipation Segment by End User/Segment
  • 4.1.1 Drugstore
  • 4.1.2 Hospital
  • 4.1.3 Others
• 4.2 Global Opioid-induced Constipation Market by End User/Segment
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Opioid-induced Constipation Market Status by Region

• 5.1 Global Opioid-induced Constipation Market by Region
• 5.2 North America Opioid-induced Constipation Market Status
• 5.3 Europe Opioid-induced Constipation Market Status
• 5.4 Asia Pacific Opioid-induced Constipation Market Status
• 5.5 Central & South America Opioid-induced Constipation Market Status
• 5.6 Middle East & Africa Opioid-induced Constipation Market Status

6 North America Opioid-induced Constipation Market Status

• 6.1 North America Opioid-induced Constipation Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Opioid-induced Constipation Market Status

• 7.1 Europe Opioid-induced Constipation Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Opioid-induced Constipation Market Status

• 8.1 Asia Pacific Opioid-induced Constipation Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Opioid-induced Constipation Market Status

• 9.1 Central & South America Opioid-induced Constipation Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Opioid-induced Constipation Market Status

• 10.1 Middle East & Africa Opioid-induced Constipation Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Opioid-induced Constipation Market Forecast by Category and by End User/Segment

• 12.1 Global Opioid-induced Constipation Sales Value Forecast (2022-2027)
• 12.2 Global Opioid-induced Constipation Forecast by Category
• 12.3 Global Opioid-induced Constipation Forecast by End User/Segment

13 Global Opioid-induced Constipation Market Forecast by Region/Country

• 13.1 Global Opioid-induced Constipation Market Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Theravance
  • 14.1.1 Company Information
  • 14.1.2 Opioid-induced Constipation Product Introduction
  • 14.1.3 Theravance Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Takeda Pharmaceutical
  • 14.2.1 Company Information
  • 14.2.2 Opioid-induced Constipation Product Introduction
  • 14.2.3 Takeda Pharmaceutical Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 Synergy Pharmaceuticals
  • 14.3.1 Company Information
  • 14.3.2 Opioid-induced Constipation Product Introduction
  • 14.3.3 Synergy Pharmaceuticals Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Sucampo
  • 14.4.1 Company Information
  • 14.4.2 Opioid-induced Constipation Product Introduction
  • 14.4.3 Sucampo Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 SLA Pharma
  • 14.5.1 Company Information
  • 14.5.2 Opioid-induced Constipation Product Introduction
  • 14.5.3 SLA Pharma Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Shionogi
  • 14.6.1 Company Information
  • 14.6.2 Opioid-induced Constipation Product Introduction
  • 14.6.3 Shionogi Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Progenics Pharmaceuticals
  • 14.7.1 Company Information
  • 14.7.2 Opioid-induced Constipation Product Introduction
  • 14.7.3 Progenics Pharmaceuticals Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Pfizer
  • 14.8.1 Company Information
  • 14.8.2 Opioid-induced Constipation Product Introduction
  • 14.8.3 Pfizer Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Nektar Therapeutics
  • 14.9.1 Company Information
  • 14.9.2 Opioid-induced Constipation Product Introduction
  • 14.9.3 Nektar Therapeutics Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Mundipharma
  • 14.10.1 Company Information
  • 14.10.2 Opioid-induced Constipation Product Introduction
  • 14.10.3 Mundipharma Opioid-induced Constipation Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Merck
• 14.12 Johnson and Johnson
• 14.13 Ironwood Pharmaceuticals
• 14.14 GlaxoSmithKline
• 14.15 Daiichi Sankyo
• 14.16 Daewoong
• 14.17 Cosmo Pharmaceuticals
• 14.18 C.B. Fleet
• 14.19 Boehringer Ingelheim
• 14.20 Bayer
• 14.21 Bausch Health
• 14.22 AstraZeneca
• 14.23 Abbott

15 Conclusion

16 Methodology